Rhumbline Advisers Ginkgo Bioworks Holdings, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.28 - $1.16 $372,940 - $1.55 Million	-1,331,930 Reduced 90.45%	140,659 $46,000
Q1 2024 May 09, 2024	SELL	$1.06 - $1.67 $213,751 - $336,758	-201,652 Reduced 12.04%	1,472,589 $1.71 Million
Q4 2023 Feb 08, 2024	BUY	$1.26 - $1.79 $65,436 - $92,961	51,934 Added 3.2%	1,674,241 $2.83 Million
Q3 2023 Nov 09, 2023	SELL	$1.61 - $2.54 $5,404 - $8,526	-3,357 Reduced 0.21%	1,622,307 $2.94 Million
Q2 2023 Aug 08, 2023	BUY	$1.14 - $1.95 $821,819 - $1.41 Million	720,894 Added 79.68%	1,625,664 $3.02 Million
Q1 2023 May 11, 2023	BUY	$1.2 - $2.19 $68,410 - $124,849	57,009 Added 6.72%	904,770 $1.2 Million
Q4 2022 Feb 14, 2023	BUY	$1.63 - $3.52 $170,677 - $368,579	104,710 Added 14.09%	847,761 $1.43 Million
Q3 2022 Nov 10, 2022	BUY	$0.73 - $3.74 $1,059 - $5,430	1,452 Added 0.2%	743,051 $2.32 Million
Q2 2022 Aug 11, 2022	BUY	$2.2 - $4.2 $1.53 Million - $2.92 Million	696,381 Added 1540.05%	741,599 $1.77 Million
Q4 2021 Feb 10, 2022	BUY	$8.31 - $14.92 $375,761 - $674,652	45,218 New	45,218 $376,000

48M

Ticker DNA
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,287,779,968
Market Cap $19B
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.